NCT06323148: Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)
- State
- Not started
- Phase
- Phase 3
- People
- 226 planned
- Started
- 1 Apr 2024
- Primary completion
- 31 Mar 2026
- Arms
- ct-DNA-positive patients receiving adjuvant osimertinib
- Results
- None posted
- 21 Mar 2024: Trial registered